Fenbendazole

Discover the integrative oncology potential of fenbendazole—a veterinary antiparasitic now under investigation for anticancer use. This course, led by Dr. Nathan Goodyear, examines fenbendazole’s impact on cancer cell metabolism, microtubule function, immune activation, and apoptosis. Participants will explore its pharmacology, off-label use in humans, safety profile, and synergy with metabolic therapies. Through clinical context and current evidence, practitioners will gain insight into how fenbendazole may complement comprehensive cancer protocols targeting multiple hallmarks of cancer.

Ivermectin

Explore the emerging role of ivermectin in oncology with Dr. Nathan Goodyear. This course examines the mechanisms behind ivermectin’s anti-cancer effects—including immune modulation, apoptosis, angiogenesis inhibition, and reversal of drug resistance. You’ll learn about pharmacokinetics, safety, dosing, and clinical applications in integrative protocols. Designed for practitioners, this module equips you to critically evaluate ivermectin’s potential as a repurposed therapy in cancer care, with a focus on evidence, synergy, and patient-centered strategies.

Mebendazole

Delve into the promising use of mebendazole, a well-established antiparasitic, as a repurposed agent in oncology. Led by Dr. Nathan Goodyear, this course explores mebendazole’s anticancer mechanisms—such as microtubule disruption, apoptosis induction, and antiangiogenic effects. You’ll learn about its pharmacokinetics, dosing strategies, synergy with conventional therapies, and safety considerations. Designed for integrative practitioners, this module offers evidence-based insight into how mebendazole may target multiple cancer hallmarks and support metabolic approaches to care.